Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia

Following 1-yr deferasirox therapy in the ESCALATOR study, 57% of previously chelated patients with β-thalassaemia achieved treatment success (maintenance of or reduction in liver iron concentration (LIC) vs. baseline LIC). Seventy-eight per cent had dose increases at median of 26 wk, suggesting tha...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Taher, Ali, Elalfy, Mohsen S, Al Zir, Kusai, Daar, Shahina, Al Jefri, Abdullah, Habr, Dany, Kriemler-Krahn, Ulrike, El-Ali, Ali, Roubert, Bernard, El-Beshlawy, Amal
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Blackwell Publishing Ltd 2011
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3229712/
https://ncbi.nlm.nih.gov/pubmed/21668502
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1600-0609.2011.01662.x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak